Articles by Xuejing Aimee Wang
99 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
ByKomal L. Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Phillippe Aftimos,Cristina Saura,Joyce O’Shaughnessy, MD,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,Junichiro Watanabe,Elgene Lim, MBBS, FRACP, PhD,Juan Huang,Qingyuan Zhang,Antonio Llombart-Cussac,Chiun-Sheng Huang,Bhardwaj Desai,Xuejing Aimee Wang,Shanshan Cao,Francois Clement Bidard 101 Patient-Reported Outcomes (PROs) in Patients With ER+, HER2- Advanced Breast Cancer (ABC) Treated with Imlunestrant, Investigator’s Choice Standard Endocrine Therapy, or Imlunestrant+Abemaciclib: Results From the Phase III EMBER-3 Trial
ByGiuseppe Curigliano,Joyce O'Shaughnessy, MD,François-Clément Bidard,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Lisa A. Carey, MD,Meena Okera,Everton Melo,Flora Zagouri,Manuel Ernesto Magallanes Maciel,Nuri Karadurmus,Shakeela Bahadur,Rebecca M Speck,Xuejing Aimee Wang,Suzanne Young,Komal L. Jhaveri,Nadia Harbeck, MD, PhD
